Using the HypoCCS database, Child et al. [78] reported the incidence of primary neoplasia in a cohort of 8418 patients treated with GH, as well as in 3668 GH-treated patients with history of pituitary adenoma and 956 GH-treated patients with history of craniopharyngiomas. This evidence concerns the gene GH1 and neoplasm.